Mutations critical for GBM classification play a significant role in tumorigenesis, with key genes such as O6 methylguanine methyltransferase (MGMT), isocitrate dehydrogenase (IDH1/2), p53, epidermal growth factor receptor (EGFR), PDGFR, PTEN, PI3K, 1p/19q chromosome deletion, and few others serving as biomarkers of disease aggressiveness and potential targets for treatment [7]. This evidence concerns the gene MGMT and glioblastoma.